Ovid Therapeutics reports Q4 2023 financial results and pipeline updates; soticlestat Phase 3 enrollment complete

Ovid Therapeutics Inc.

Soticlestat Phase 3 trials for Lennox-Gastaut and Dravet syndromes completed enrollment; Takeda expects topline data by September 2024.
Cash and marketable securities of $105.8M as of Dec 31, 2023; expected runway into first half of 2026.
OV888 (GV101) Phase 1 multiple-ascending dose study progressing; no serious adverse events; higher dose cohort added.
Net loss of $52.3M for full year 2023 compared to $54.2M in 2022; basic net loss per share $0.74.
Ovid retains 87% interest in soticlestat milestones and royalties; potential payments up to $660M plus low double-digit royalties.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Ovid Therapeutics Inc. reported financial results for the fourth quarter and year ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Business Update, Fourth Quarter and Full Year 2023 Financial Results

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Ovid Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-009807

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.